<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00433316</url>
  </required_header>
  <id_info>
    <org_study_id>CMC064113CTIL</org_study_id>
    <secondary_id>HT 3758</secondary_id>
    <nct_id>NCT00433316</nct_id>
  </id_info>
  <brief_title>Pain Relief by Intra-Peritoneal Ropivacaine During Gynecological Laparoscopy</brief_title>
  <official_title>Pain Relief by Continuous Intra-Peritoneal Nebulization of Ropivacaine During Gynecological Laparoscopic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carmel Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carmel Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In our prospective, randomized, placebo controlled and double-blinded study we will study the
      efficacy of intraperitoneal ropivacaine nebulization on pain relief during gynecological
      laparoscopic surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VAS score</measure>
    <time_frame>early post-operative</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Laparoscopic Surgical Procedures</condition>
  <arm_group>
    <arm_group_label>study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receiving 10ml of 1% ropivacaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Receiving 10ml of saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ropivacaine</intervention_name>
    <description>1% ropivacaine</description>
    <arm_group_label>study</arm_group_label>
    <other_name>Narop</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aeroneb Pro Nezulizer, Aerogen, Ireland</intervention_name>
    <description>Aeroneb Pro Nezulizer, Aerogen, Ireland</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elective gynecologic laparoscopic surgery including unilateral or bilateral
             salpingo-oopherectomy or ovarian cystectomy.

          -  The patient is not participating in other medical study at present or in the last 30
             days.

          -  The patient signed on an informed consent.

          -  Age 18 years and above.

          -  ASA (American Society of Anesthesiologists) physical status grade 1- 2.

        Exclusion Criteria:

          -  Allergy to Ropivacaine, other local anesthetics or other medications listed in the
             protocol.

          -  The patient is participating in other medical experiment at present or in the last 30
             days.

          -  Acute Pelvic Inflammatory Disease.

          -  Coumadin or Aspirin treatment.

          -  ASA physical status grade 3-4.

          -  Age &lt; 18 years.

          -  Significant arrythmias

          -  Analgesic treatment for chronic pain
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuval Kaufman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Carmel Medical Center, Haifa, Israel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reuven Pizov, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Carmel Medical Center, Haifa, Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>the Carmel Medical Center Ambulatory Gynecoendoscopic Unit</name>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>February 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2007</study_first_submitted>
  <study_first_submitted_qc>February 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2007</study_first_posted>
  <last_update_submitted>June 19, 2008</last_update_submitted>
  <last_update_submitted_qc>June 19, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2008</last_update_posted>
  <responsible_party>
    <name_title>Yuval Kaufman</name_title>
    <organization>Carmel Medical Center</organization>
  </responsible_party>
  <keyword>ropivacaine</keyword>
  <keyword>laparoscopy</keyword>
  <keyword>intraperitoneal</keyword>
  <keyword>nebulization</keyword>
  <keyword>pain</keyword>
  <keyword>local analgesic</keyword>
  <keyword>gynecology</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

